Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;27(11):633-642.
doi: 10.1111/gtc.12980. Epub 2022 Aug 25.

The TIGD5 gene located in 8q24 and frequently amplified in ovarian cancers is a tumor suppressor

Affiliations
Free article

The TIGD5 gene located in 8q24 and frequently amplified in ovarian cancers is a tumor suppressor

Yuntao Dai et al. Genes Cells. 2022 Nov.
Free article

Abstract

Ovarian cancer (OC) is the fifth most common cancer of female cancer death and leading cause of lethal gynecological cancers. High-grade serous ovarian carcinoma (HGSOC) is an aggressive malignancy that is rapidly fatal. Many cases of OC show amplification of the 8q24 chromosomal region, which contains the well-known oncogene MYC. Although MYC amplification is more frequently observed in OCs than in other tumor types, due to the large size of the 8q24 amplicon, the functions of the vast majority of the genes it contains are still unknown. The TIGD5 gene is located at 8q24.3 and encodes a nuclear protein with a DNA-binding motif, but its precise role is obscure. We show here that TIGD5 often co-amplifies with MYC in OCs, and that OC patients with high TIGD5 mRNA expression have a poor prognosis. However, we also found that TIGD5 overexpression in ovarian cancer cell lines unexpectedly suppressed their growth, adhesion, and invasion in vitro, and also reduced tumor growth in xenografted nude mice in vivo. Thus, our work suggests that TIGD5 may in fact operate as a tumor suppressor in OCs rather than as an oncogene.

Keywords: 8q24; MYC; TIGD5; ovarian cancer; tumor suppressor.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Abugessaisa, I., & Kasukawa, T. (2021). Practical guide to life science databases. Springer.
    1. Baker, V. V., Borst, M. P., Dixon, D., Hatch, K. D., Shingleton, H. M., & Miller, D. (1990). C-myc amplification in ovarian cancer. Gynecologic Oncology, 38, 340-342.
    1. Bowtell, D. D., Bohm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Jr., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., Brenton, J. D., Chiappinelli, K. B., Martins, F. C., Coukos, G., Drapkin, R., Edmondson, R., Fotopoulou, C., Gabra, H., Galon, J., … Pharoah, P. (2015). Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer, 15, 668-679.
    1. Breyer, J. P., Dorset, D. C., Clark, T. A., Bradley, K. M., Wahlfors, T. A., McReynolds, K. M., Maynard, W. H., Chang, S. S., Cookson, M. S., Smith, J. A., Schleutker, J., Dupont, W. D., & Smith, J. R. (2014). An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. American Journal of Human Genetics, 94, 395-404.
    1. Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.